Abstract: Edit automation functionality generalizes edits performed by a user in a document, locates similar text, and recommends or applies transforms while staying within a current workflow. Source code edits such as refactoring are automated. The functionality uses or provides anchor target lists, temporal edit patterns, edit graphs, automatable edit sequence libraries, and other data structures and computational techniques for identifying locations appropriate for particular edits, for getting transforms, for selecting optimal transforms, for leveraging transforms in an editing session or later, and for displaying transform recommendations and results. The edit automation functionality enhances automation subtool generation, discoverability, and flexibility, for refactoring, snippet insertion, quick actions in an integrated development environment, and other automatable edit sequences.

Abstract: Historic context data is automatically associated with particular pieces of source code by retrieval data structures. Ephemeral information is preserved, such as how a piece of code originated operationally and was changed over time, which research sources informed the code's origination and changes, and why particular changes in the code were made. Code may be rolled back to an earlier version based on parameters such as whether code had been refactored, or results of testing or static analysis. Rollback goes beyond editor undo actions, and a developer need not specify a timestamp or a version number. Developer documentation burdens are reduced, developer understanding is increased, and code quality is enhanced, by providing ready access to the code's software development context history data. Some actions made possible include highlighting code that was generated automatically by autocompletion or otherwise, highlighting refactored code, and highlighting pasted code, among other actions.

Abstract: A colloidal silica solution which includes two or more colloidal silica compositions or suspensions having differing particle sizes and specific surface areas, the compositions or suspensions resulting in a multimodal particle size distribution in which the solution or suspension can be bimodal in nature and composed of, but not limited to, particles with a mode of 4 nm and 20 nm or composed of particles 7 nm and 12 nm. The solution or suspension can also be trimodal and composed of, but not limited to, 4 nm, 7 nm and 15 nm or 3 nm, 5 nm, and 20 nm. The solution or suspension can also include other multimodal systems which would give superior water drainage and fiber and ash retention on paper machines. The colloidal silica solution is a drainage and retention aid in the making of paper.

Abstract: A colloidal silica solution which includes two or more colloidal silica compositions or suspensions having differing particle sizes and specific surface areas, the compositions or suspensions resulting in a multimodal particle size distribution in which the solution or suspension can be bimodal in nature and composed of, but not limited to, particles with a mode of 4 nm and 20 nm or composed of particles 7 nm and 12 nm. The solution or suspension can also be trimodal and composed of, but not limited to, 4 nm, 7 nm and 15 nm or 3 nm, 5 nm, and 20 nm. The solution or suspension can also include other multimodal systems which would give superior water drainage and fiber and ash retention on paper machines. The colloidal silica solution is a drainage and retention aid in the making of paper.

Abstract: An automated or semi-automated module-based cartilage cell processing device (20) for preparing a cell seeded carrier (27a) from a biological material, comprising at least a cartilage preparation module (21), a cell isolation module (22), a cell mixing module (29) and a carrier cell seeding module (29a). The invention further relates to the individual modules of the module-based cartilage cell processing device (20).

Abstract: The present invention provides methods of treatment with a pharmaceutical composition, more particularly a sustained release pharmaceutical composition, comprising 11-[4-[2-(2-hydroxyethoxy)ethyl]-1-piperazinyl]dibenzo-[b,f][1,4]thiazepine or a pharmaceutically acceptable salt thereof, as well as new and improved methods for treating a variety of psychological disorders and conditions including, but not limited to, Mood Disorders and Anxiety Disorders and for treating one or more of the symptoms of these disorders.

Abstract: The present invention provides methods for treating depression symptoms associated with bipolar disorder.

Abstract: The present invention provides methods of treatment with a pharmaceutical composition, more particularly a sustained release pharmaceutical composition, comprising 11-[4-[2-(2-hydroxyethoxy)ethyl]-1-piperazinyl]dibenzo-[b,f][1,4]thiazepine or a pharmaceutically acceptable salt thereof, as well as new and improved methods for treating a variety of psychological disorders and conditions including, but not limited to, Mood Disorders and Anxiety Disorders and for treating one or more of the symptoms of these disorders.

Abstract: The present invention provides methods for treating depression symptoms associated with bipolar disorder.